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Abstract
Candida albicans is a normal inhabitant of the skin and mucosal membranes of
humans, however, in individuals with depressed immune systems or disrupted cutaneous
flora, Candida can overgrow and cause serious infection. Candida infection is the fourth
leading cause of nosocomial infection in the United States. These infections are often
associated with longer hospital stays and higher mortality. Current drug therapies for this
infection are largely ineffective due to the increased drug resistance of Candida species,
and for some therapeutics, high levels of drug toxicity to humans. Histatin 5 is a naturally
occurring salivary peptide that has strong antifungal properties. Derivatives of this
peptide, including KM12 and KM23, have been previously tested in the McNabb lab, and
have shown as much as ten times more fungicidal activity than Histatin 5. Our current
understanding of the mechanism by which these peptides kill has not been fully
characterized. This study uses Saccharomyces cerevisiae as a genetically tractable model
to investigate one of the proposed target mechanisms of KM23, namely respiratory
metabolism. Respiratory mutants were tested to determine which gene knockouts
conferred cell resistance to KM23. If resistance was present for the mutant, the
corresponding gene product is part of the killing mechanism of KM23. ATP synthase
mutants, atp1Δ, atp2Δ, atp5Δ, and atp7Δ, were the main focus of this study. It was found
that atp1Δ, atp5Δ, and atp7Δ conferred resistance of the yeast cells to KM23, while atp2Δ
did not show significant resistance. It was subsequently found that atp2Δ was not truly
respiratory deficient, therefore, we conclude that ATP synthase function is imperative to
the overall killing action of KM23, supporting prior observations that respiratory
metabolism is necessary for killing by Histatin 5 and Histatin 5-related peptides.
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Introduction
Candida albicans is a species of fungi that inhabits the human body on the skin and in
mucosal membranes. This organism is an opportunistic pathogen, meaning that it lives on
the human body harmlessly as part of the normal flora, until the host’s immune response
is lowered, due to other concurrent diseases or certain drug therapies. Candida albicans is
a unicellular, diploid fungus that exists in 3 phases: budding yeast, pseudohyphae, and
hyphae (Calderone & Fonzi, 2001). At room temperature and under anaerobic conditions,
Candida albicans exists in the budding yeast form. In this state, the yeast colonies are
oval-shaped, smooth, and white or cream colored (Calderone & Fonzi, 2001). However,
under physiological conditions, this organism can convert to the hyphal or pseudohyphal
form. In these filamentous states, the cells remain attached to each other after budding
and elongate to form filaments, which are tubular, thread-like structures (Sudbery, Gow,
Berman, 2004). This dimorphism is thought to aid in the virulence of Candida albicans
(Calderone & Fonzi, 2001).

Candida infections manifest in three main types: oropharyngeal candidiasis, genital or
vulvovaginal candidiasis, and systemic candidiasis. These infections occur due to an
overgrowth of Candida species caused by a lowered host immune response or a reduction
in other resident bacteria that normally compete with this organism. In intensive care
units worldwide, candidemia infection has a prevalence of 6.9 per 1000 patients
(Mikulska M, 2012). Individuals who are most affected by candidiasis include
immunocompromised patients, such as those undergoing treatment for HIV/AIDS or
cancer, low-birth-weight infants, diabetics, and individuals using corticosteroids or
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broad-spectrum antibiotics (CDC 2014). Candidiasis is associated with high mortality
and increased hospital stays (Paramythiotou E, 2014). It is estimated that the mortality
attributable to candidiasis is 19-24% (Morgan J 2005). A yeast infection in the mouth or
throat, commonly termed “thrush”, if left unchecked could enter the bloodstream and
spread systemically, causing further complications in a patient’s condition. Candida
infections are the fourth most common nosocomial bloodstream infection in the United
States (Paramythiotou E, 2014).

There are multiple classes of antifungal drugs currently on the market, which attack
different aspects of Candida species to treat infections. These drug classes include azoles,
polyenes, pyrimidine analogs, and echinocandins. Azoles, such as miconazole and
fluconazole, are the most commonly prescribed (Paramythiotou E, 2014). This class
affects the composition of fungal plasma membranes through the inhibition of ergosterol
synthesis by binding to the cytochrome P-450-dependent enzyme lanosterol demethylase
in the fungal cell (Sheehan, Hitchcock, Sibley, 1999). This is an effective drug
mechanism because mammalian cell membranes contain cholesterol rather than
ergosterol, and because azoles have a greater affinity for the fungal enzyme associated
with sterol synthesis than they do for the mammalian enzyme. However, the incidences
of azole-resistant strains of Candida species has risen in recent years due to chronic use
of fluconazole and itraconazole in prophylactic measures and to treat oropharyngeal and
vaginal candidiasis (Mulu et al., 2013), making it a less effective drug to combat Candida
infections. An alternative drug class is the polyenes, such as amphotericin B and nystatin,
which bind to ergosterol within the cell membrane and create transmembrane channels,
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leading to membrane instability and cell lysis (Laniado-Laborin, Cabrales-Vargas, 2009).
Unfortunately, polyenes, especially amphotericin B, have a high affinity for cholesterol
as well as ergosterol. For this reason, they are associated with numerous negative side
effects, including renal failure after long-term use (Bondaryk, Kurzatkowski, &
Staniszewska, 2013). The third class of antifungal drugs, pyrimidine analogs, like
flucytosine, act like pyrimidine bases, affecting protein synthesis by incorporating into
RNA and disturbing the normal coding regions (Bondaryk et al., 2013). The main
enzyme that allows this drug to act, cytosine deaminase, is not present in mammalian
cells, buffering them from the effects of this drug while acting on the fungal agent.
However, this class of drugs is usually restricted to use in a multi-drug therapy regimen,
due to its high incidence of resistance and possible negative side effects, including bone
marrow suppression and liver dysfunction. The final class of major antifungal drugs is
echinocandins. This class of drugs acts on the cell membrane of fungi by inhibiting the
synthesis of 1,3-β-glucan synthase, eventually leading to cell wall instability and cell
lysis. This drug is effective against azole-resistant Candida yeasts, but has many negative
side effects including liver toxicity and hemolysis (Bondaryk et al., 2013). In addition,
many of the drug interactions between antifungal drugs and other medications are
negative or can be synergistic, leading to various complications in treatment, especially in
those which candidiasis as a secondary infection.

The current methods of treatment for candidiasis are neither sufficient nor ideal due to
their overall high incidence of Candida species resistance and adverse side effects on the
patient. In addition, the increased occurrence of infection by non-albicans Candida
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species, which can be resistant to current drug therapies, creates a need for the
development and investigations of new treatment routes. Histatin 5
(DSHAKRHHGYKRKFHEKHHSHRGY) is a naturally occurring peptide that resides in
the saliva of humans and displays strong fungicidal properties, making it a prime model
for new antifungal drugs (Helmerhorst EJ, 1999). Histatin 5 contains 24 amino acid
residues and is histidine-rich, making it highly cationic (Oppenheirn et al., 1988). It binds
to cell wall proteins and glycans upon initial cell interactions. Histatin 5 is then taken up
by yeast cells through fungal polyamine transporters in an energy dependent manner
(Puri S & Edgerton M, 2014). Although histatins have been widely studied, their
mechanism of killing action is not fully mapped out.

There are two current models describing the mechanism of this peptide. One proposal is
that the entry of histatin 5 ultimately leads to ion imbalance in the fungal cell due to
increased cell membrane permeability (Wang G, 2014). The second proposal is that the
target of this peptide is mitochondrial, and that it acts to inhibit the normal respiratory
pathway of the fungus, causing oxidative stress (Mochon AB and Lui H, 2008). In other
studies, it has been shown that sodium azide and other respiration inhibitors protect yeast
cells against the lethal activity of histatin 5 (Helmerhorst EJ, 1999). While this
observation is useful, chemical manipulation of the cells could affect more than just the
yeast’s respiratory function. The hope is that by further elucidating the mechanism of
action for histatin 5 and its derivatives, these peptides can be promoted and explored as
possible novel antifungal drugs.
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KM23, an inverted dimer, is the principal derivative of histatin 5 focused on in this
study. In Dr. McNabb’s lab, previous work has thoroughly characterized KM12
(YKRKFC-CFKRKY). This peptide is very similar to KM23 in killing activity, with
slight structural differences. The LD50 for KM12 on C. albicans was determined to be
0.308±0.035 µM (Akkam Y, 2013). KM12 had similar ability to kill S. cerevisiae and C.
albicans. The activity of this derivative, KM12, is ten times more active than histatin 5
alone (Akkam Y, 2013). KM23 and KM12 are inhibited in the presence of histatin 5
inhibitors, such as low temperature and sodium azide, and are therefore suggested to have
a similar mode of action to histatin 5 (Akkam Y, 2013). In order to further map the
mechanism of action of histatin 5 and its derivatives, the effects of KM23 on the
genetically tractable model yeast, Saccharomyces cerevisiae, has been tested.

Saccharomyces cerevisiae serves as a good model organism for Candida albicans
because these organisms are closely related to each other, (Li, Palecek, 2005) and they
are both susceptible to the killing action of histatin 5 and our derivative peptides.
Saccharomyces cerevisiae grows rapidly, in small, smooth, cream to tan colored colonies.
This species of yeast replicates by budding like Candida albicans, but has a haploid
instead of a diploid genome. S. cerevisiae serves as a prevalent model organism because
it has well characterized genes and is easily manipulated due to its haploid genome. The
logic of this study is to identify mutations in the electron transport chain, more
specifically the ATP synthase of S. cerevisiae, that confer resistance to KM23. Any
mutant that causes resistance to killing by KM23 is likely involved in the peptide’s
mechanism of killing action, which we hypothesize is localized in the mitochondria.
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Unlike, chemical means of testing for killing inhibition, testing genetic knockouts focuses
on a single trackable protein subunit. In other studies, it has been shown that respiratory
enzyme complexes, including proteins involved in the ATP synthase gamma chain and
malate dehydrogenase, were mostly down-regulated when Candida albicans was treated
with histatin 5 (Komatsu T, 2011). S. cerevisiae mutants located in the ATP synthase of
the electron transport chain, including atp1∆, atp2∆, atp5∆ and atp7∆, were tested to
examine KM23’s mechanism of action.

Figure 1. ATP synthase and S. cerevisiae respiratory mutants. Figure adapted from
Rak M, 2011. Yeast mitochondrial ATP synthase protein subunits and corresponding
knockout mutants.

The F1F0-ATP synthase of S. cerevisiae consists of two functional domains, the globular
F1 protein and the membrane-bound F0 protein. These two domains couple to catalyze
ATP synthesis and proton translocation across the inner mitochondrial membrane (Rak
2011). The electroosmotic potential created by the transport of protons across the
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membrane is used to synthesize ATP from ADP and Pi. These two functional domains are
connected by both a central and a stator stalk (Devenish 2000). This connection aids in
the rotation of subunits within the enzyme that catalyzes the movement of protons across
the inner membrane. The various protein subunits of the F1F0-ATP synthase of S.
cerevisiae were knocked out and purchased as a library. atp1Δ, atp2Δ, atp5Δ, and atp7Δ
were tested (Figure 1). While these mutants are essential to ATP synthase functioning,
their deletion is not lethal to the yeast cells. These mutants are still able to undergo
fermentation to produce ATP on YPD medium (Norais 1991). However, any substrate
that cannot be utilized through glycolysis and alcoholic fermentation, glycerol for
example, will inhibit the growth of the mutant yeast strains.

The atp1Δ and atp2Δ are subunits of the F1 functional domain of the mitochondrial ATP
synthase (Takeda 1986). They comprise an alternating hexamer of catalytic subunits that
are involved in ATPase activity. atp1Δ is a knockout mutation of the α-subunit and atp2Δ
is a knockout mutation of the β-subunit of the F1 functional domain (Takeda 1986, 1985).
atp5Δ and atp7Δ are mutations of subunits within the stator stalk of ATP synthase
(Devenish 2000). atp5Δ is the OSCP or oligomycin sensitivity-conferring protein (Boyer
1997) and atp7Δ is a knockout mutation of the d-subunit of the stator stalk (Norais 1991).
Both of these subunits are normally involved in proton translocation and rotation of the
F1 and F0 functional domains.
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Methods and Materials
Saccharomyces cerevisiae strains and growth media. The wild-type Saccharomyces
strain was BY4741 (MATa, his3Δ1, leu2Δ0, met15Δ0, ura3Δ0). In addition, four
mitochondrial ATP synthase mutants, atp1Δ, atp2Δ, atp5Δ, and atp7Δ were used in this
study. The mutants were isogenic derivatives of BY4741 and they were purchased from
Dharmacon as part of a genome-wide S. cerevisiae knockout collection. All strains were
grown in Yeast extract-peptone-dextrose (YPD) liquid culture 24 hours prior to the
beginning of each assay (Guthrie and Fink, 1991). Strains were grown on YPD agar
plates during each assay. Yeast extract-peptone-glycerol (YPG) was prepared as
described (Guthrie and Fink, 1991).

KM23 peptide. The stock KM23 peptide was purchased from Gene Script, where it was
synthesized and purified. The 50 µM stock peptide (YKRKFFKRKY) was diluted to 2
µM with 10 mM phosphate-buffered saline (PBS) for each microdilution assay.

Microdilution Assay. Prior to each independent assay, 5 mL YPD liquid medium was
inoculated for each S. cerevisiae strain to be tested. These strains were grown at 30°C
overnight. On the day of the assay, 1 mL of each strain was transferred to a 1.5 mL
eppendorf tube. The tubes were centrifuged for 10 min at 14,000 rpm. The supernatant
was discarded, and 1 mL of 10 mM sodium phosphate buffer (PB) was added to each
tube. The pellet was resuspended, and the tubes were centrifuged for another 10 min at
14,000 rpm. The supernatant was again discarded. The pellet of each tube was
resuspended a second time with 1 mL PB and vortexed. The cells were quantified on a
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hemocytometer. The cell count was input into an Excel counting sheet, which computed
the amount needed to have 3.6 × 106 cells in 1 mL of PB (10X stock solution of cells).
This amount of cells, for each respective strain, was inoculated in 1 mL PB. Then in a
second set of tubes, 900 µL of PB was inoculated with 100 µL of the prepared 10X stock
of cells to bring the final concentration to 3.6 × 105 cells in 1 mL of PB. Next, 20 µL of
the diluted cells were placed into two eppendorf tubes: one with 20 µL PB, the other with
20 µL 2 µM KM23. These eppendorf tubes, two for each strain, were placed in the
incubator at 30°C and shaken at 320 rpm for 2 hours. After incubation, the tubes were
removed, and 360 µL of yeast nitrogen base was added to each tube. The tubes were then
vortexed before being plated. Two replicates of each tube were made on YPD agar plates.
All of the plates were incubated at 30°C for 48 hours. After this incubation period, the
colony forming units were counted on each plate. The average of the two replicates was
taken and the cell viability was calculated.
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Results
For evaluating the killing activity of KM23 in each of the strains, a concentration of
KM23 was chosen that yielded approximately 50% cell viability when used with the
wild-type strain, BY4741. Thus, 1 µM final concentration of the KM23 peptide was used
in these studies. The logic for this choice was to provide for the ability to observe either
increased resistance or increased sensitivity to the peptide for the various mutants
evaluated.

Microdilution assays were performed for the wild-type and the atp1∆, atp2∆, atp5∆ and
atp7∆ mutants. It should be noted that the assays were performed in duplicates for each
trial and a minimum of three independent trials were performed with each mutant. For
the wild-type there were thirteen independent experiments, the atp1∆ and atp2∆ mutants
were tested in five independent trials, and the atp5∆ and atp7∆ mutants were evaluated in
three independent trials. After conducting the microdilution assays, the data for all the
mutants was compiled and statistically analyzed using an unpaired student T-test. The
atp1Δ, atp5Δ, and atp7Δ showed significant resistance to KM23, with virtually 100%
viability after exposure to 1µM KM23 as compared to the wild-type strain, which
exhibited less than 50% cell viability (Figure 2). The atp2Δ demonstrated variable results
and did not show any significant resistance to KM23 (Figure 2). This was a particularly
surprising and unexpected observation. Since the atp2Δ mutant was one knockout strain
from a large collection of over 4,900 individual S. cerevisiae strains, it was plausible that
the knockout mutation was not correct and that the putative atp2Δ mutant was not as
advertised by the company from where it was purchased.
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Figure 2. Mutation in the ATP Synthase confers resistance to KM23. Microdilution
assays were performed as described in the Materials and Methods. Each of the strains
were evaluated in duplicate with a minimum of three independent trials. The average
percent cell viability is shown with the bars indicating the standard error. The data was
evaluated using an unpaired student T- test and the statistical significance is indicated.
NS denotes no statistical difference from the wild-type strain.
In order to address this concern, the wild-type strain and the atp1∆, atp2∆, atp5∆ and
atp7∆ mutants were streaked on YPD medium, containing glucose as the carbon source,
and YPG medium, containing glycerol as the carbon source. Strains that could grow on
YPG are not respiratory deficient because they are able to generate ATP through
respiration by the oxidation of glycerol, a three-carbon substrate. Strains that could only
grow on YPD were able to generate ATP via fermentation of the glucose present in the
YPD medium, but could not utilize non-fermentable carbon sources. It was found that
the wild-type strain grew on YPG as expected. More importantly, it was observed that the
atp2Δ mutant grew well on YPG medium confirming that it is not respiratory deficient.
This data suggests that the atp2Δ mutant may not be truly deficient in its abilities to
respire; hence, our observation that it was not resistant to the KM23 peptide. One can
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also note that even on YPD, the respiration defective strains are clearly distinguishable by
the difference in the growth phenotype. The respiratory mutants (atp1Δ, atp5Δ, atp7Δ)
failed to grow as robustly as the wild-type or the atp2Δ mutant due to the depletion of
glucose from the medium.

Figure 3. The respiratory phenotype of the putative ATP Synthase mutants. The
wild type, atp1∆, atp2∆, atp5∆ and atp7∆ mutants as indicated were streaked on either
YPD medium or YPG medium and grown at 30oC for 3 days.
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Discussion
Multiple other studies have referenced the possible importance of the mitochondrion in
the killing mechanism of histatin 5 and its derivatives (Mochon AB and Lui H, 2008)
(Helmerhorst EJ, 1999). Previous studies used chemical methods, which have led to
uncertain conclusions and the need for a more targeted approach. Through testing
respiratory mutants of several subunits within the ATP synthase in S. cerevisiae, we were
able to specifically target the electron transport chain within the mitochondria. The
mutants we used were gene knockouts for each subunit within the F1F0-ATP synthase of
S. cerevisiae. KM23 cannot act without this molecular target within the yeast cell.
Mutants that conferred resistance to KM23, the histatin 5 derivative peptide, are involved
in the killing mechanism of the peptide. atp1Δ, atp5Δ, and atp7Δ show this trend, having
significant resistance to KM23 in comparison to the cell viability of the mutants in the
presence of the buffer. atp2Δ was not significantly resistant to the lethal effects of KM23;
however, it was also shown to not be respiratory deficient. Interestingly though, this
mutant still provided an unknown internal control for our studies and further emphasized
the importance of respiration in the killing action of our peptide.

The inability of the atp2Δ mutant to protect itself against KM23 acts as unintentional
support for our hypothesis. After testing the respiratory abilities of atp2Δ by growing the
mutants on fermentable and non-fermentable carbon sources, we found that the atp2Δ
strain was not in fact a full gene knockout. It was able to grow on YPG, forcing the cells
to respire using glycerol as the primary carbon source and thereby, the electron transport
chain to produce energy (Figure 3). Therefore, the atp2Δ strain that we assumed did not
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have a functional ATP synthase, did in fact have the enzyme. KM23 was able to bind to
and act on this strain, just as it could in the wild-type yeast, because the intracellular
target was present. This study shows that ATP synthase activity in S. cerevisiae is crucial
to the killing activity of KM23.

Further support for the role of the mitochondria in the mechanism of KM23 activity
comes from the recent Honors thesis of Gabriela Morris, another student in the McNabb
laboratory. In those studies, the KM23 peptide was fluorescently labeled and fluorescent
microscopy was used to determine the intracellular localization of the peptide. It was
found that KM23 localizes exclusively to the mitochondria, lending further support to the
model that respiratory metabolism is important for the killing mechanism of KM23.

The question arises as to whether other mutations in the electron transport chain would
yield similar KM23-resistant phenotypes or whether this is exclusively associated with
the ATP synthase. Future studies should be directed toward examining mutants in
subunits of Complex I, Complex II, Complex III and Complex IV of the electron
transport chain to determine whether those mutations confer resistance to KM23.
Nevertheless, identifying the target pathways involved in peptide resistance does not
provide details on the mechanism by which the KM23 peptide is fungicidal. Since S.
cerevisiae does not require functional respiration for survival, it poses the question as to
why mutations that abolish respiration result in resistance to the peptide. Is abundant
ATP production essential? Does reduced ATP synthesis influence other pathways, such
as energy-dependent transporters, that may be the actual target of KM23 killing?
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In order to further study the mechanism of KM23 it must be determined whether
respiration in general is required for the lethal activity of KM23, or whether the
intracellular target is more specific. In the McNabb lab, students are currently screening a
library of approximately 5000 S. cerevisiae mutants to determine all possible genetic
pathways involved in the fungicidal activity of KM23. This includes mutations within the
other complexes of the electron transport chain. In addition, it will be important in future
studies to test respiratory mutants in C. albicans and other Candida species to compare
the pathways affected by KM23.
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